Xa inhibition and coagulation activity-the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals

American Heart Journal

Volumn 155, Issue 3, 2008, Pages 493.e1-493.e8

  Oldgren, Jonas ^a   Johnston, Nina ^a   Siegbahn, Agneta ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; CALCIUM CHANNEL BLOCKING AGENT; D DIMER; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; INSULIN; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; PLACEBO; PROTHROMBIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

EID: 39149142857     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.12.006     Document Type: Article

References (29)

1. Falk E., Shah P.K., and Fuster V. Coronary plaque disruption. Circulation 92 (1995) 657-671
2. Topol E.J., and Yadav J.S. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101 (2000) 570-580
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
4. Maseri A., Liuzzo G., and Biasucci L.M. Pathogenic mechanisms in unstable angina. Heart 82 Suppl 1 (1999) I2-I4
5. al-Nozha M., Gader A.M., al-Momen A.K., et al. Haemostatic variables in patients with unstable angina. Int J Cardiol 43 (1994) 269-277
6. Gerotziafas G.T., Zafiropoulos A., Van Dreden P., et al. Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina. Br J Haematol 120 (2003) 611-617
7. Kruskal J.B., Commerford P.J., Franks J.J., et al. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 317 (1987) 1361-1365
8. Merlini P.A., Ardissino D., Oltrona L., et al. Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol 15 (1995) 1675-1679
9. Ossei-Gerning N., Wilson I.J., and Grant P.J. Sex differences in coagulation and fibrinolysis in subjects with coronary artery disease. Thromb Haemost 79 (1998) 736-740
10. Kalaria V.G., Zareba W., Moss A.J., et al. Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction. The THROMBO Investigators. Am J Cardiol 85 (2000) 1401-1408
11. Ernofsson M., Strekerud F., Toss H., et al. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost 79 (1998) 491-494
12. Gori A.M., Fedi S., Pepe G., et al. Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration. Br J Haematol 117 (2002) 693-698
13. Bijsterveld N.R., Moons A.H., Meijers J.C., et al. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 39 (2002) 811-817
14. Oldgren J., Fellenius C., Boman K., et al. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease. J Intern Med 258 (2005) 420-427
15. FRIS C-II. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 354 (1999) 701-707
16. FRIS C-II. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 354 (1999) 708-715
17. Johnston N., Jernberg T., Lindahl B., et al. Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin Biochem 37 (2004) 210-216
18. Eikelboom J.W., Anand S.S., Malmberg K., et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 355 (2000) 1936-1942
19. Montalescot G., Collet J.P., Tanguy M.L., et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 110 (2004) 392-398
20. Li Y., Rodriquez M., Spencer F.A., et al. Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance. J Thromb Thrombolysis 14 (2002) 123-129
21. Becker R.C., Spencer F.A., Li Y., et al. Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential. J Am Coll Cardiol 34 (1999) 1020-1027
22. Hurlen M., Abdelnoor M., Smith P., et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347 (2002) 969-974
23. Wallentin L., Wilcox R.G., Weaver W.D., et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362 (2003) 789-797
24. Miller G.J., Bauer K.A., Barzegar S., et al. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost 75 (1996) 767-771
25. Ridker P.M., Hennekens C.H., Cerskus A., et al. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 90 (1994) 2236-2240
26. Lowe G.D., Yarnell J.W., Sweetnam P.M., et al. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 79 (1998) 129-133
27. Granger C.B., Becker R., Tracy R.P., et al. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 31 (1998) 497-505
28. Oldgren J., Linder R., Grip L., et al. Clinical outcome and coagulation activity in unstable coronary artery disease. Arterioscler Thromb Vasc Biol 21 (2001) 1059-1064
29. Lindmark E., Wallentin L., and Siegbahn A. Blood cell activation, coagulation, and inflammation in men and women with coronary artery disease. Thromb Res 103 (2001) 249-259